This is a synthetic peptide designed for use in combination with anti-NFKBIB antibody (Catalog #: ARP34382_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
Each Investigator should determine their own optimal working dilution for specific applications.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
Konzentration
1 mg/mL
Buffer
Final peptide concentration is 1 mg/mL in PBS.
Handhabung
Avoid repeated freeze-thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
Target
NFKBIB
(NF-kappa-B inhibitor beta (NFKBIB))
Hintergrund
NFKB1 (MIM 164011) or NFKB2 (MIM 164012) is bound to REL (MIM 164910), RELA (MIM 164014), or RELB (MIM 604758) to form the NFKB complex. The NFKB complex is inhibited by I-kappa-B proteins (NFKBIA, MIM 164008, or NFKBIB), which inactivate NF-kappa-B by trapping it in the cytoplasm. Phosphorylation of serine residues on the I-kappa-B proteins by kinases (IKBKA, MIM 600664 or IKBKB, MIM 603258) marks them for destruction via the ubiquitination pathway, thereby allowing activation of the NF-kappa-B complex. Activated NFKB complex translocates into the nucleus and binds DNA at kappa-B-binding motifs such as 5-prime GGGRNNYYCC 3-prime or 5-prime HGGARNYYCC 3-prime (where H is A, C, or T, R is an A or G purine, and Y is a C or T pyrimidine).[supplied by OMIM].
Alias Symbols: IKBB, TRIP9
Protein Interaction Partner: IKBKB,MCC,RELA,RELA,BTRC,CD3EAP,CHUK,CUL1,IKBKB,IKBKG,KPNA2,LRPPRC,MCC,MTIF2,NFKB1,NFKB2,NFKBIA,NGFR,NKIRAS1,NKIRAS2,PDCD2,POLR1A,POLR1B,POLR1C,POLR1D,POLR1E,POLR2H,POLR2L,RASAL2,REL,RELA,RXRA,SKP1,BTRC,CHUK,IKBKB,NKIRAS1,REL,RELA,RXRA,Thrb